

Neurex Symposium 10/02/2023


Focused ultrasound (FUS) and indirect neuromodulation

Jonathan Vappou

Robotics, Data Science and Healthcare Technologies team (RDH) ICube Laboratory jvappou@unistra.fr




Therapetic Ultrasound : Mechanisms of action





The first therapeutic Ultrasound device: 1953



1953 Frontal lobotomy on 20 patients (craniotomy)

Courtesy B. Larrat, CEA/Neurospin



The Fry Brothers

1950s~1970s



A PRECISION FOCUSSED-ULTRASOUND GENERATOR For NEUROPHYSIOLOGICAL and NEUROLOGICAL RESEARCH*





Inspected pre-calificated assess bands will be observed on their develops and there is no consultily of observations of any executing exponence in the foreseeable bases. For factors information, action to




tral P Colores Proved

RADIONICS, INC.




Therapeutic Ultrasound Timeline



Gail Ter Haar, History of Focused Ultrasound, ISTU 2020



Common clinical indications




Gastrointestinal	Inflammatory bowel disease Irritable bowel syndrome
Miscellaneous	 Heterotopic ossification Infection Kaposi's sarcoma
Musculoskeletal	Osteopenia
Neurological	😑 Mood disorder
Ophthalmological	 Retinal impairment Retinal injury
Women's Health	 Hyperplasia of the vulva Lichen sclerosis
	Development stage
	Preclinical

Source: fusfoundation




FUS and brain






7

FUS and brain





Thermal FUS: Transcranial approach






InSightec Exablate Neuro




Thermal FUS: Transcranial approach

Videos from the FUS Foundation



Awake, no anesthesia No incisions No burr holes No electrodes No infection No blood clots No brain damage







FUS ablation and psychiatry

Molecular Psychiatry https://doi.org/10.1038/s41380-020-0737-1

IMMEDIATE COMMUNICATION




Magnetic resonance-guided focused ultrasound capsulotomy for refractory obsessive compulsive disorder and major depressive disorder: clinical and imaging results from two phase I trials

Benjamin Davidson^{1,2,3} · Clement Hamani^{1,2,3} · Jennifer S. Rabin^{2,3,4} · Maged Goubran^{2,3,5,6} · Ying Meng^{1,2,3} · Yuexi Huang³ · Anusha Baskaran^{2,3} · Sachie Sharma^{2,3} · Miracle Ozzoude^{2,3} · Margaret Anne Richter^{2,3,7,8} · Anthony Levitt^{2,3,8} · Peter Giacobbe^{2,3,8} · Kullervo Hynynen^{2,3,5,6} · Nir Lipsman^{1,2,3}

Received: 11 December 2019 / Revised: 1 April 2020 / Accepted: 15 April 2020 © Springer Nature Limited 2020




FUS ablation and psychiatry



- Preliminary study that illustrates feasibility and safety of the proposed approach
- Encouraging clinical results (N=12)
- 4/16 patients excluded due to non accessibility of the target (ExAblate is designed for targeting the thalamus)



FUS and brain







The challenge of treating brain diseases

Most pharmacological treatment strategies for central nervous system (CNS) disorders are ineffective

Δ

- > 95% of drugs do not cross the Blood-brain barrier (BBB).
- Global failure of pharmacological therapy of the central nervous system.





Tight junctions

Blood-brain barrier (BBB)




BBB Opening using ultrasound




Brain blood barrier opening video from Queensland Brain Institute -



BBB Opening using ultrasound





Marty et al., J Cereb Blood Flow Metab, 2012

✓ Transient and reversible ✓ Highly localized ✓ Safe when cavitation is properly monitored



BBB opening: Indications (Oncology)

Courtesy B. Larrat, CEA/Neurospin

Clinical trial	Indication	ication Drug Device		Phase	Primary outcome measures
registration n°	mulcation	Diug	Device	rnase	Primary outcome measures
NCT03712293	GBM	Temozolomide	ExAblate®	N/A	Safety
NCT04440358	rGBM	Carboplatin	ExAblate®	Phase I/II	Safety/Feasibility
NCT04417088	rGBM	Carboplatin	ExAblate®	Phase I/II	Safety/Feasibility
NCT03616860	GBM	Temozolomide	ExAblate®	N/A	Safety
NCT03551249	GBM	Temozolomide	ExAblate®	N/A	Safety
NCT04998864	GBM	Temozolomide	ExAblate®	N/A	Safety/Feasibility
		Liposomal			
NCT02343991	Brain tumor	doxorubicin	ExAblate®	N/A	Safety
		or temozolomide			
NCT02253212	rGBM	Carboplatin	SonoCloud-1®	Phase I/II	Safety
NCT03744026	rGBM	Carboplatin	SonoCloud-9®	Phase I/II	Safety/Feasibility
NCT04614493	GBM	Temozolomide	SonoCloud-9®	Phase II	Efficacy (PFS)
		Abraxane® (Phase I)			
NCT04528680	rGBM	Carboplatin/	SonoCloud-9®	Phase I/II	Safety/Efficacy (1-year survival rate)
		Abraxane [®] (Phase II)			(1-year survivarrate)
NCT03626896	rGBM	N/A	NaviFUS [®]	N/A	Safety
NCT04446416	rGBM	Bevacizumab	NaviFUS [®]	N/A	Safety/Efficacy (PFS-6 months)

GBM: glioblastoma, rGBM: recurrent glioblastoma, PFS: progression-free survival,



BBB opening: Indications (Neurodegenerative diseases)

NCT04118764	Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound (safety)	Columbia University, NYC	Neuronavigation
NCT03671889	ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease (safety)	InSighTec, multicentric, USA	MR-guided
NCT03321487	Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis (safety => BBBo in motor cortex)	InSighTec, Sunnybrook Health Science Center, Toronto, Canada	MR-guided
NCT04370665	Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease	InSighTec, Sunnybrook Health Science Center, Toronto, Canada	MR-guided



BBB opening and psychiatry?



Behavioural Brain Research

Volume 342, 16 April 2018, Pages 57-61



Short communication

Antidepressant effects of focused ultrasound induced blood-brain-barrier opening

<u>Skyler J. Mooney</u>^a ♀ ⊠, <u>José N. Nobrega</u>^{cd}, <u>Anthony J. Levitt</u>^{bc}, <u>Kullervo Hynynen</u>^{a e}

Show more 🗸

=> Neurogenesis ?
=> Long-term changes in neural excitability?
"neuromodulatory potential of FUS-mediated BBB opening"



BBB opening and psychiatry?




RESEARCH ARTICLE


Focused Ultrasound-Induced Neurogenesis Requires an Increase in Blood-Brain Barrier Permeability

Skyler J. Mooney 🗃, Kairavi Shah, Sharon Yeung, Alison Burgess, Isabelle Aubert, Kullervo Hynynen

Published: July 26, 2016 • https://doi.org/10.1371/journal.pone.0159892



With microbubbles (BBB open)



Without microbubbles



Non-invasive BBB Opening using Ultrasound

MR-guided

Neuronavigation



InsighTech (Israel), ExAblate Neuro NaviFUS (Taiwan) Columbia University (NY, USA)


Major challenge = BBB opening on extended volumes



The Therasonic device

New FUS device for opening BBB, robotized, neuronavigated, outside MRI









The Therasonic device

New FUS device for opening BBB, robotized, neuronavigated, outside MRI





Volumetric BBB opening





Thank you!





TechnoFUS joint laboratory ICube- Image Guided Therapy

Information Sciences and Technology for Healthcare | HealthTech The Interdisciplinary thematic institutes of the University of Strasbourg 6 @ 6 @ Inserm Insert the Excellence initiative gragment (2)